EGF-IL-18 fusion protein as a potential anti-tumor reagent by induction of immune response and apoptosis in cancer cells.
We report here the generation and characterization of EGF-IL-18 fusion protein as an anti-tumor reagent. The epidermal growth factor (EGF) and interleukin-18 (IL-18) fusion protein was shown to induce interferon-gamma (IFNgamma) expression and secretion in KG-1 cells, and to promote PBMNC proliferation. It also stimulated activation of CD4+ T cells, and increased other immune responses. Moreover, EGF-IL-18 could induce significant tumor regression in SMMC-7721-xenografted Balb/c nude mice when administered together with peritumoral injection of X-ray-irradiated NK-92 cells, and this regression is associated with arresting of the tumor cells in G1 phase and induction of apoptosis.
Lu
Jianxin
J
Institute of Molecular & Cellular Medicine, Wenzhou Medical College, Wenzhou 325035, PR China.
Peng
Y
Y
Zheng
Z J
ZJ
Pan
J H
JH
Zhang
Yangde
Y
Bai
Yidong
Y
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000201:enzymology; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D066246:ErbB Receptors / Q000187:drug effects / Q000378:metabolism; D005260:Female; D016193:G1 Phase; D006801:Humans; D007107:Immune System / Q000187:drug effects* / Q000378:metabolism; D036341:Intercellular Signaling Peptides and Proteins; D007371:Interferon-gamma / Q000378:metabolism; D020382:Interleukin-18 / Q000494:pharmacology* / Q000627:therapeutic use; D020014:K562 Cells; D007694:Killer Cells, Natural / Q000187:drug effects / Q000528:radiation effects; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010455:Peptides / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors; D014760:Viral Fusion Proteins / Q000494:pharmacology* / Q000627:therapeutic use; D014965:X-Rays; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; C527799:EGF-IL-18 fusion protein, mouse; D036341:Intercellular Signaling Peptides and Proteins; D020382:Interleukin-18; D010455:Peptides; D014760:Viral Fusion Proteins; C051087:vaccinia growth factor; D007371:Interferon-gamma; D066246:ErbB Receptors